EcoDrugPlus

Dopamine Receptor D2

Ensembl ID : ENSCGOG00000017590
Gene Symbol: DRD2
3 Cross references
207 Possible Orthologues:

Dopamine Receptor D4b

Ensembl ID : ENSCGOG00000010856
Gene Symbol: DRD4B
1 Cross references
174 Possible Orthologues:

Dopamine Receptor D5

Ensembl ID : ENSCGOG00000001098
Gene Symbol: DRD5
3 Cross references
148 Possible Orthologues:

Dual Specificity Mitogen-Activated Protein Kinase Kinase 2-Like

Ensembl ID : ENSCGOG00000012380
Gene Symbol: LOC115022522
3 Cross references
202 Possible Orthologues:

Ectonucleotide Pyrophosphatase/phosphodiesterase 2

Ensembl ID : ENSCGOG00000022768
Gene Symbol: ENPP2
3 Cross references
226 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSCGOG00000011161
Gene Symbol: EGLN1
3 Cross references
216 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 2

Ensembl ID : ENSCGOG00000008610
Gene Symbol: EGLN2
3 Cross references
195 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 3

Ensembl ID : ENSCGOG00000013359
Gene Symbol: EGLN3
3 Cross references
200 Possible Orthologues:

Endothelial Pas Domain-Containing Protein 1-Like

Ensembl ID : ENSCGOG00000022481
Gene Symbol: LOC115020043
3 Cross references
212 Possible Orthologues:

Endothelin Converting Enzyme 1

Ensembl ID : ENSCGOG00000013555
Gene Symbol: ECE1
3 Cross references
231 Possible Orthologues:

Endothelin Receptor Type A

Ensembl ID : ENSCGOG00000007285
Gene Symbol: EDNRA
3 Cross references
205 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSCGOG00000013553
Gene Symbol: EDNRB
3 Cross references
178 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).